期刊
FUTURE MICROBIOLOGY
卷 13, 期 9, 页码 971-983出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fmb-2018-0054
关键词
beta-lactam; beta-lactamase; beta-lactamase inhibitor; carbapenem; carbapenem-resistant Enterobacteriaceae; Gram-negative; Klebsiella pneumoniae carbapenemase; meropenem and vaborbactam
类别
资金
- National Institute of Allergy and Infectious Diseases (DMID) [10-0065, R01-AI119446-01]
- The Medicines Company
- Melinta
- Merck
- Allergand
- Achaogen
- Tetraphase
- Shionogi
- Zavante
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI119446] Funding Source: NIH RePORTER
Meropenem-vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid beta-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE). The efficacy of meropenem-vaborbactam for the treatment of complicated urinary tract infections and acute pyelonephritis was demonstrated in a Phase III trial (TANGO I). Preliminary data from TANGO II, a separate Phase III study, support the efficacy of meropenem-vaborbactam for the treatment of infections caused by CRE. Overall, meropenem-vaborbactam appears to be safe and well tolerated. It has favorable toxicity, pharmacokinetic and pharmacodynamic profiles compared with other antibiotics with activity against CRE. Meropenem-vaborbactam is an important addition to the current armamentarium of antimicrobial agents with activity against K. pneumoniae carbapenemase-producing CRE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据